The round, which includes $140m from AstraZeneca, was announced alongside a Zika vaccine-related US government grant that could reach $125m in size.
US-based messenger RNA therapeutics developer Moderna Therapeutics announced $474m in equity financing today that included a $140m investment by pharmaceutical company AstraZeneca last month.
Moderna did not disclose any precise investors in the round, describing them as “existing institutional investors and world-class strategic pharmaceutical partners as well as…new institutional investors from the United States, Europe and Asia”.
However, a regulatory filing on indicates Moderna had closed $451m for the round as of August 24, and had begun raising the…